593 related articles for article (PubMed ID: 33059626)
1. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
[TBL] [Abstract][Full Text] [Related]
2. The combined use of anti-peptic agents is associated with an increased risk of osteoporotic fracture: a nationwide case-control study.
Oh DJ; Nam JH; Lee HS; Moon YR; Lim YJ
Korean J Intern Med; 2024 Mar; 39(2):228-237. PubMed ID: 38321358
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
Park JH; Song YM; Jung JH; Han K
Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
[TBL] [Abstract][Full Text] [Related]
4. Long-term proton pump inhibitor therapy and risk of hip fracture.
Yang YX; Lewis JD; Epstein S; Metz DC
JAMA; 2006 Dec; 296(24):2947-53. PubMed ID: 17190895
[TBL] [Abstract][Full Text] [Related]
5. Association between proton pump inhibitor use and risk of fracture: A population-based case-control study.
Kim JJ; Jang EJ; Park J; Sohn HS
PLoS One; 2020; 15(7):e0235163. PubMed ID: 32730257
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
[TBL] [Abstract][Full Text] [Related]
7. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies.
Yu EW; Bauer SR; Bain PA; Bauer DC
Am J Med; 2011 Jun; 124(6):519-26. PubMed ID: 21605729
[TBL] [Abstract][Full Text] [Related]
9. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.
Lee J; Youn K; Choi NK; Lee JH; Kang D; Song HJ; Park BJ
J Gastroenterol; 2013 Sep; 48(9):1016-22. PubMed ID: 23307040
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes.
Chou YS; Jiang HJ; Chen CH; Ho PS; Lee TC
Sci Rep; 2020 Aug; 10(1):14081. PubMed ID: 32826941
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of gastroesophageal reflux disease in Korea and associated health-care utilization: a national population-based study.
Kim KM; Cho YK; Bae SJ; Kim DS; Shim KN; Kim JH; Jung SW; Kim N
J Gastroenterol Hepatol; 2012 Apr; 27(4):741-5. PubMed ID: 21916988
[TBL] [Abstract][Full Text] [Related]
12. Peptic Ulcer Disease and Risk of Hip Fracture: A General Population-based Cohort Study.
Li J; Lu N; Lyu H; Lei G; Zeng C; Wei J; Wang Y; Xie D
J Clin Endocrinol Metab; 2022 Aug; 107(9):e3738-e3746. PubMed ID: 35689555
[TBL] [Abstract][Full Text] [Related]
13. Long-term continuous use of proton-pump inhibitors is associated with renal function decline in patients without acute kidney injury.
Hatakeyama Y; Horino T; Matsumoto T; Terada Y; Okuhara Y
Clin Exp Nephrol; 2021 Oct; 25(10):1087-1092. PubMed ID: 34089392
[TBL] [Abstract][Full Text] [Related]
14. Associations between Proton Pump Inhibitor and Histamine-2 Receptor Antagonist and Bone Mineral Density among Kidney Transplant Recipients.
Lyu B; Hansen KE; Jorgenson MR; Astor BC
Am J Nephrol; 2020; 51(6):433-441. PubMed ID: 32485707
[TBL] [Abstract][Full Text] [Related]
15. Drugs for GERD and peptic ulcer disease.
Med Lett Drugs Ther; 2018 Jan; 60(1538):9-16. PubMed ID: 29309399
[No Abstract] [Full Text] [Related]
16. Comparison of fracture risk between proton pump inhibitors and histamine-2 receptor antagonists in ANCA-associated vasculitis patients: a nested case-control study.
Miyano S; Michihata N; Sada KE; Uda K; Matsui H; Fushimi K; Nangaku M; Yasunaga H
Rheumatology (Oxford); 2021 Apr; 60(4):1717-1723. PubMed ID: 33067623
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
18. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response.
Ruigómez A; Johansson S; Wernersson B; Fernández Cantero O; García Rodríguez LA
Scand J Gastroenterol; 2012 Jul; 47(7):751-61. PubMed ID: 22519917
[TBL] [Abstract][Full Text] [Related]
19. Comparison table: Drugs for GERD and peptic ulcer disease.
Med Lett Drugs Ther; 2018 Jan; 60(1538):e16-e18. PubMed ID: 29309400
[No Abstract] [Full Text] [Related]
20. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis.
Chen CH; Lin CL; Kao CH
Osteoporos Int; 2016 Jun; 27(6):2117-26. PubMed ID: 26860609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
